

Application  
Number

SEARCH

IDS Flag Clearance for Application

10532245

IDS  
Information

Content



Mailroom Date

Entry Number

IDS Review

Reviewer

UPDATE



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

chain bonds :

2-8 4-7

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-14 7-17 8-9 8-13 9-10 10-11 11-12 12-13 14-15  
15-16 16-17 16-18 17-21 18-19 19-20 20-21

exact/norm bonds :

1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 7-14 7-17 8-9 8-13 9-10 10-11 11-12 12-13  
14-15 15-16

normalized bonds :

16-17 16-18 17-21 18-19 19-20 20-21

isolated ring systems :

containing 1 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

10523,245

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/CAPplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAPplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/CAPplus - Expanded coverage of German academic research
NEWS	12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS	13	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS EXPRESS			DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT <a href="http://download.cas.org/express/v8.0-Discover/">http://download.cas.org/express/v8.0-Discover/</a>
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:37:25 ON 10 DEC 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10523,245

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:37:31 ON 10 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 DEC 2005 HIGHEST RN 869698-41-9  
DICTIONARY FILE UPDATES: 9 DEC 2005 HIGHEST RN 869698-41-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.



REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10532245.str

10523,245



ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21  
chain bonds :  
2-8 4-7  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-14 7-17 8-9 8-13 9-10 10-11 11-12 12-13  
14-15 15-16 16-17 16-18 17-21 18-19 19-20 20-21  
exact/norm bonds :  
1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 7-14 7-17 8-9 8-13 9-10 10-11 11-12  
12-13 14-15 15-16  
normalized bonds :  
16-17 16-18 17-21 18-19 19-20 20-21  
isolated ring systems :  
containing 1 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10523,245



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:37:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 93 TO 587

PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> d scan


L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 3-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI)

MF C19 H24 N8 O2

CI COM


10523,245



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1H-Benzimidazol-5-ol, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI)  
MF C20 H22 F2 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI)  
MF C21 H25 F2 N7 O2


Relative stereochemistry.

10523,245



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(tetrahydro-2-methyl-1,4-oxazepin-4(5H)-yl)-2-pyrimidinyl]- (9CI)  
MF C21 H26 N6 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-6-nitro- (9CI)  
MF C20 H21 F2 N7 O4




10523,245



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI)  
MF C22 H27 F2 N7 O2


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1H-Benzimidazole, 1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI)  
MF C20 H25 N7 O2

10523,245



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful

FULL SEARCH INITIATED 10:38:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 301 TO ITERATE

100.0% PROCESSED 301 ITERATIONS

168 ANSWERS

SEARCH TIME: 00.00.01

L3 168 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.76

161.97

FILE 'CAPLUS' ENTERED AT 10:38:39 ON 10 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2005 VOL 143 ISS 25

FILE LAST UPDATED: 9 Dec 2005 (20051209/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l4

L4 NOT FOUND

The L-number entered has not been defined in this session, or it

10523,245

has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l3

L4 7 L3

=> d l4 1-7 bib hitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:1103774 CAPLUS

DN 143:367324

TI Preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and  
2-benzimidazolyl-4,6-dimorpholinyltriazine derivatives as antitumor agents  
IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Tsuchida,  
Yoshio; Saitoh, Kenichi; Watanabe, Tetsuo

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005095389	A1	20051013	WO 2005-JP6111	20050330
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI JP 2004-103273 A 20040331

IT 866392-54-3P 866392-55-4P 866392-56-5P

866392-57-6P 866392-58-7P 866392-59-8P

866392-60-1P 866392-61-2P 866392-62-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and 2-benzimidazolyl-4,6-dimorpholinyltriazine derivs. as antitumor agents)

RN 866392-54-3 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10523,245



RN 866392-55-4 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 866392-56-5 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 866392-57-6 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6R)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866392-58-7 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-4-methoxy- (9CI) (CA INDEX NAME)


10523,245



RN 866392-59-8 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-4-methoxy-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



RN 866392-60-1 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-4-methoxy-1-[4-(4-morpholinyl)-6-(2,2,5,5-tetramethyl-4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



10523,245


RN 866392-61-2 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-4-ethoxy- (9CI) (CA INDEX NAME)



RN 866392-62-3 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-ethoxy- (9CI) (CA INDEX NAME)



IT 866392-64-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and 2-benzimidazolyl-4,6-dimorpholinyltriazine derivs. as antitumor agents)

RN 866392-64-5 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-pyrimidinyl]-2-(difluoromethyl)-4-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:370924 CAPLUS

DN 140:375193

TI Preparation of heterocyclic compounds and antitumor drugs containing the same as the active ingredient

IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Tsuchida, Yoshio; Saito, Kenichi; Sasahara, Hiroya; Watanabe, Tetsuo

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037812	A1	20040506	WO 2003-JP13589	20031024
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503451	AA	20040506	CA 2003-2503451	20031024
	EP 1557415	A1	20050727	EP 2003-758850	20031024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	JP 2002-311086	A	20021025		
	WO 2003-JP13589	W	20031024		
OS	MARPAT 140:375193				
IT	685111-07-3P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of 2-(1-benzimidazolyl)-4-morpholino-1,3,5-triazine or -pyrimidine derivs. as antitumor drugs)				
RN	685111-07-3 CAPLUS				
CN	1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)				






IT **685111-02-8P**, 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholinopyrimidine **685111-03-9P**, 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **685111-04-0P**, 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine **685111-05-1P**, 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-[methyl(1-methylpiperidin-4-yl)amino]-6-morpholino-1,3,5-triazine **685111-06-2P**, 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine **685111-08-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(1-benzimidazolyl)-4-morpholino-1,3,5-triazine or -pyrimidine derivs. as antitumor drugs)

RN 685111-02-8 CAPLUS

CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-[2-(hydroxymethyl)-1-pyrrolidinyl]-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 685111-03-9 CAPLUS


CN 1H-Benzimidazol-6-amine, 4-chloro-2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

CN1=CC=C(C=C1C2=NC(=N2)N(C3=NC(=NC(=N3)N4CCOCC4)C5=CC=CC=C5)C(F)(F)F)C6=CC(=CC=C6)Cl

CN 2-Pyrrolidinemethanol, 1-[4-[6-amino-4-chloro-2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




CN 1H-Benzimidazol-6-amine, 4-chloro-2-(difluoromethyl)-1-[4-[methyl(1-methyl-4-piperidiny) amino]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-[2-(hydroxymethyl)-1-pyrrolidinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245



RN 685111-08-4 CAPLUS

CN 1H-Benzimidazol-5-ol, 4-chloro-2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)




IT **685111-12-0P**, 2-[4-(tert-Butyldimethylsilyloxy)-2-(difluoromethyl)benzimidazol-1-yl]-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholinopyrimidine **685111-14-2P**, 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-chloro-6-morpholino-1,3,5-triazine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-(1-benzimidazolyl)-4-morpholino-1,3,5-triazine or -pyrimidine derivs. as antitumor drugs)

RN 685111-12-0 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[2-(difluoromethyl)-4-[(1,1-dimethylethyl)dimethylsilyl]oxy]-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 685111-14-2 CAPLUS

10523,245

CN 1H-Benzimidazol-6-amine, 4-chloro-1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:202751 CAPLUS

DN 142:176724

TI Product subclass 3: 1,3,5-triazines and phosphorus analogues

AU von Angerer, S.

CS Bad Abbach, 93077, Germany

SO Science of Synthesis (2004), 17, 449-583

CODEN: SSCYJ9

PB Georg Thieme Verlag

DT Journal; General Review

LA English


IT 220229-25-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(review preparation of triazines and their phosphorus analogs via cyclization, ring transformation, aromatization, and substituent modification)

RN 220229-25-4 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI)  
(CA INDEX NAME)



RE.CNT 592 THERE ARE 592 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:849619 CAPLUS

DN 137:370113

TI Preparation of heterocyclic compounds as antitumor agents

IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Sasahara, Hiroya; Watanabe, Tetsuo

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002088112	A1	20021107	WO 2002-JP4227	20020426
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
CA 2445395 AA 20021107 CA 2002-2445395 20020426  
EP 1389617 A1 20040218 EP 2002-722829 20020426  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
CN 1538967 A 20041020 CN 2002-812617 20020426  
US 2004116421 A1 20040617 US 2003-475094 20031027  
PRAI JP 2001-132250 A 20010427  
WO 2002-JP4227 W 20020426  
OS MARPAT 137:370113  
IT **475110-93-1P**, 2-(2-Difluoromethylbenzimidazol-1-yl)-4-morpholino-6-  
thiomorpholino-1,3,5-triazine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of heterocyclic compds. as antitumor agents)  
RN 475110-93-1 CAPLUS  
CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-(4-  
thiomorpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



IT **475110-78-2P 475110-79-3P**, 2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine  
**475110-80-6P**, 2-(2-Difluoromethylbenzimidazol-1-yl)-4-morpholino-6-thiomorpholinopyrimidine **475110-81-7P 475110-82-8P**,  
2-(2-Difluoromethylbenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholinopyrimidine **475110-83-9P**, 2-(2-Difluoromethylbenzimidazol-1-yl)-4-(2-methylmorpholino)-6-morpholinopyrimidine **475110-84-0P 475110-85-1P**  
**475110-86-2P 475110-87-3P 475110-88-4P**  
**475110-89-5P 475110-90-8P 475110-91-9P**  
**475110-92-0P**, 2-(2-Difluoromethylbenzimidazol-1-yl)-4-(2,3-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475110-94-2P**,  
2-(2-Difluoromethylbenzimidazol-1-yl)-4-(2-methylmorpholino)-6-morpholino-1,3,5-triazine **475110-95-3P 475110-96-4P**,  
2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine  
**475110-97-5P 475110-98-6P 475110-99-7P**,  
2-(2-Acetylamino benzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine  
**475111-00-3P 475111-01-4P**, 2-(2-Formylaminobenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine **475111-02-5P**  
**475111-03-6P 475111-04-7P 475111-05-8P**  
**475111-06-9P**, 2-(2-Methoxycarbonylamino benzimidazol-1-yl)-4,6-

bis(morpholino)-1,3,5-triazine **475111-07-0P 475111-08-1P**  
**475111-09-2P**, 2-(6-Amino-2-difluoromethylbenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475111-10-5P**  
**475111-12-7P**, 2-(4-Amino-2-difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine **475111-15-0P**,  
 2-(6-Amino-2-difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine **475111-17-2P 475111-19-4P**  
**475111-21-8P**, 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475111-23-0P**  
 , 2-(2-Difluoromethyl-5-hydroxybenzimidazol-1-yl)-4-(2,2-dimethylloxazolidin-3-yl)-6-morpholino-1,3,5-triazine **475111-25-2P**  
 , 2-(2-Difluoromethyl-5-hydroxybenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as antitumor agents)

RN 475110-78-2 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 475110-79-3 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 475110-80-6 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-(4-thiomorpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

C(F)Fc1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N3CCSCC3)c1

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


C[C@H]1S[C@@H](CN2C=CN(C3C=CC(=N3)N4C(=N2)C(=C5C=CC=CC=C5N4C(F)(F)F)C6=CC=CC=C6)C7=CC=CC=C7)S[C@H]1C2

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2-methyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10523,245



RN 475110-84-0 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-[(5R)-2,2,5-trimethyl-4-morpholinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475110-85-1 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-[(5S)-2,2,5-trimethyl-4-morpholinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475110-86-2 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10523,245

morpholinyl]-2-pyrimidinyl]-2-(fluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475110-87-3 CAPLUS

CN 1H-Benzimidazole-2-methanol, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475110-88-4 CAPLUS

CN 1H-Benzimidazole-2-methanol, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(1-piperidinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 475110-89-5 CAPLUS

CN 1H-Benzimidazole-2-methanol, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-[2-(hydroxymethyl)-1-pyrrolidinyl]-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475110-90-8 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245

RN 475110-91-9 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475110-92-0 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,3-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 475110-94-2 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2-methyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 475110-95-3 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,5S)-2,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

10523,245


NAME)

Relative stereochemistry.



RN 475110-96-4 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)



RN 475110-97-5 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-[(5R)-2,2,5-trimethyl-4-morpholinyl]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 475110-98-6 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-(1-oxido-4-


10523,245

thiomorpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 475110-99-7 CAPLUS


CN Acetamide, N-[1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 475111-00-3 CAPLUS

CN Acetamide, N-[1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-01-4 CAPLUS

CN Formamide, N-[1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)


10523,245



RN 475111-02-5 CAPLUS

CN Propanamide, N-[1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-03-6 CAPLUS

CN Formamide, N-[1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245

RN 475111-04-7 CAPLUS

CN Formamide, N-[1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-05-8 CAPLUS

CN Formamide, N-[1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-06-9 CAPLUS

CN Carbamic acid, [1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)


10523,245



RN 475111-07-0 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●x HCl


RN 475111-08-1 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245



● x HCl

RN 475111-09-2 CAPLUS


CN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 475111-10-5 CAPLUS

CN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



10523,245


RN 475111-12-7 CAPLUS

CN 1H-Benzimidazol-4-amine, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)



RN 475111-15-0 CAPLUS


CN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 475111-17-2 CAPLUS

CN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475111-19-4 CAPLUS

CN 1H-Benzimidazol-5-ol, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


10523,245

Relative stereochemistry.




RN 475111-21-8 CAPLUS

CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 475111-23-0 CAPLUS

CN 1H-Benzimidazol-5-ol, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-3-oxazolidinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 475111-25-2 CAPLUS

CN 1H-Benzimidazol-5-ol, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



IT **475111-30-9P 475111-33-2P 475111-35-4P**  
**475111-36-5P 475111-38-7P**, 4-Chloro-2-(2-difluoromethylbenzimidazol-1-yl)-6-morpholino-1,3,5-triazine  
**475111-39-8P**, 2-(2-Aminobenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine **475111-41-2P**, 4-Chloro-2-(2-difluoromethyl-5-nitrobenzimidazol-1-yl)-6-morpholino-1,3,5-triazine **475111-42-3P**, 4-Chloro-2-(2-difluoromethyl-6-nitrobenzimidazol-1-yl)-6-morpholino-1,3,5-triazine **475111-43-4P**, 2-(2-Difluoromethyl-5-nitrobenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475111-44-5P**, 2-(2-Difluoromethyl-6-nitrobenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475111-45-6P**, 2-(2-Difluoromethyl-5-nitrobenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine **475111-46-7P**, 2-(2-Difluoromethyl-6-nitrobenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine **475111-48-9P 475111-49-0P**, 2-(2-Difluoromethyl-5-(tert-butyltrimethylsilyloxy)benzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of heterocyclic compds. as antitumor agents)  
 RN 475111-30-9 CAPLUS  
 CN 1H-Benzimidazole, 1-[4-chloro-6-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-2-pyrimidinyl]-2-(difluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-33-2 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 475111-35-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-36-5 CAPLUS


CN 1H-Benzimidazole, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475111-38-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)- (9CI) (CA INDEX NAME)



RN 475111-39-8 CAPLUS


CN 1H-Benzimidazol-2-amine, 1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)



RN 475111-41-2 CAPLUS


CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)-5-nitro- (9CI) (CA INDEX NAME)

10523,245




RN 475111-42-3 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)-6-nitro- (9CI) (CA INDEX NAME)




RN 475111-43-4 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-5-nitro- (9CI) (CA INDEX NAME)



RN 475111-44-5 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-6-nitro- (9CI) (CA INDEX NAME)



RN 475111-45-6 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-5-nitro- (9CI) (CA INDEX NAME)

10523,245



RN 475111-46-7 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-6-nitro- (9CI) (CA INDEX NAME)



RN 475111-48-9 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-5-[[[1,1-dimethylethyl)dimethylsilyl]oxy]-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-49-0 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-5-[[[1,1-dimethylethyl)dimethylsilyl]oxy]-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)





RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2000:788207 CAPLUS  
DN 134:86200  
TI Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and  
benzimidazolylpyrimidine derivatives  
AU Matsuno, Toshiyuki; Kato, Masanobu; Sasahara, Hiroya; Watanabe, Tetsuo;  
Inaba, Masahiro; Takahashi, Masayuki; Yaguchi, Shin-Ichi; Yoshioka,  
Kimitomo; Sakato, Mitsuo; Kawashima, Seiichiro  
CS Research Laboratory, Zenyaku Kogyo Co., Ltd., Tokyo, 178-0062, Japan  
SO Chemical & Pharmaceutical Bulletin (2000), 48(11), 1778-1781  
CODEN: CPBTAL; ISSN: 0009-2363  
PB Pharmaceutical Society of Japan  
DT Journal  
LA English  
OS CASREACT 134:86200  
IT 220228-62-6P 220228-68-2P 220228-70-6P  
220228-90-0P 220228-99-9P 220229-00-5P  
220229-05-0P 316806-91-4P 316806-92-5P  
316806-93-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)  
(synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and  
benzimidazolylpyrimidine derivs.)  
RN 220228-62-6 CAPLUS  
CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA  
INDEX NAME)




RN 220228-68-2 CAPLUS  
CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-

10523,245

morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-70-6 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220228-90-0 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-(1H-benzimidazol-1-yl)-N,N-dimethyl-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 220228-99-9 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 220229-00-5 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220229-05-0 CAPLUS


CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 316806-91-4 CAPLUS


CN 1H-Benzimidazole, 1-[4-(2-methyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245



RN 316806-92-5 CAPLUS


CN 1H-Benzimidazole, 1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 316806-93-6 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 220229-25-4P 220229-29-8P 316806-94-7P  
316806-95-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivs.)

RN 220229-25-4 CAPLUS


CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245



RN 220229-29-8 CAPLUS


CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 316806-94-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 316806-95-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:513689 CAPLUS

DN 133:89550

TI Preparation of benzimidazolyltriazine derivatives as antitumor agents

IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Tsuchida, Yoshio; Sasahara, Hiroya; Watanabe, Tetsuo; Inaba, Masahiro

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000043385	A1	20000727	WO 2000-JP348	20000125
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 1999-16216	A	19990125		

OS MARPAT 133:89550


IT 282097-26-1P 282097-27-2P 282097-28-3P  
 282097-29-4P 282097-30-7P 282097-31-8P  
 282097-32-9P 282097-33-0P 282097-34-1P  
 282097-35-2P 282097-36-3P 282097-38-5P  
 282097-39-6P 282097-40-9P 282097-41-0P  
 282097-42-1P 282097-43-2P 282097-44-3P  
 282097-45-4P 282097-46-5P 282097-47-6P  
 282097-48-7P 282097-49-8P 282097-50-1P  
 282097-51-2P 282097-52-3P 282097-53-4P  
 282097-54-5P 282097-55-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antitumor activity of benzimidazolyltriazine derivs.)

RN 282097-26-1 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(2,3,6-trimethyl-4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 282097-27-2 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,5S)-2,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

10523,245


Relative stereochemistry.



RN 282097-28-3 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,5R)-2,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 282097-29-4 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(2,3,5,6-tetramethyl-4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 282097-30-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-(2-methyl-1-aziridinyl)-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10523,245



RN 282097-31-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282097-32-9 CAPLUS

CN Morpholine, 4-[[4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 282097-33-0 CAPLUS

CN Proline, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




COC(=O)N1CCCC1c2nc3nc(NC4=CN=C5C=CC=CC=C45)nc(NC6CCOCC6)n3

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(2,3,6-trimethyl-4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




1H-Benzimidazole, 1-[5-(methylthio)-4,6-di-4-morpholinyl-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)





CN 1H-Benzimidazole, 1-(5-methyl-4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI)  
(CA INDEX NAME)

10523,245




RN 282097-38-5 CAPLUS

CN 5-Pyrimidineacetic acid, 2-(1H-benzimidazol-1-yl)-4,6-di-4-morpholinyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 282097-39-6 CAPLUS

CN 5-Pyrimidineacetic acid, 2-(1H-benzimidazol-1-yl)-4,6-di-4-morpholinyl-, (9CI) (CA INDEX NAME)




RN 282097-40-9 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-5-(methylthio)-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10523,245




RN 282097-41-0 CAPLUS

CN 1H-Benzimidazole, 1-(5-methoxy-4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI)  
(CA INDEX NAME)



RN 282097-42-1 CAPLUS

CN 2-Morpholinepropanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 282097-43-2 CAPLUS

CN 2-Morpholinebutanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)


10523,245



●x HCl

RN 282097-44-3 CAPLUS


CN 2-Morpholinebutanamine, 4-[2-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 282097-45-4 CAPLUS

CN 2-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-5,6-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 282097-46-5 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, acetate (ester) (9CI) (CA INDEX NAME)

10523,245




RN 282097-47-6 CAPLUS

CN 2-Thia-5-azabicyclo[2.2.1]heptane, 5-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 282097-48-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(tetrahydro-1,4-oxazepin-4(5H)-yl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 282097-49-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(3-oxazolidinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 282097-50-1 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)


10523,245

triazin-2-yl]-, benzoate (ester) (9CI) (CA INDEX NAME)




RN 282097-51-2 CAPLUS

CN 2-Morpholinol, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 282097-52-3 CAPLUS


CN 3-Oxa-6-azabicyclo[3.1.1]heptane, 6-[2-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 282097-53-4 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(tetrahydro-1,4-oxazepin-4(5H)-yl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10523,245




RN 282097-54-5 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(tetrahydro-2-methyl-1,4-oxazin-4(5H)-yl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 282097-55-6 CAPLUS

CN 1H-Benzimidazole, 1-[4-(1-azetidiny)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



IT 282097-57-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and antitumor activity of benzimidazolyltriazine derivatives)

RN 282097-57-8 CAPLUS

CN Carbamic acid, [3-[4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-morpholinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


azepin-

in-2-

civs.)

3,5-  
(CA






IT 220229-25-4P 220229-29-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and antitumor activity of benzimidazolyltriazine derivs.)


RN 220229-25-4 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220229-29-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:96239 CAPLUS

DN 130:153673

TI Preparation of heterocyclic compounds as antitumor agents

IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Watanabe, Tetsuo; Inaba, Masahiro

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

PI	WO 9905138	A1	19990204	WO 1998-JP3308	19980724
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2297326	AA	19990204	CA 1998-2297326	19980724
	AU 9883575	A1	19990216	AU 1998-83575	19980724
	AU 727013	B2	20001130		
	EP 1020462	A1	20000719	EP 1998-933922	19980724
	EP 1020462	B1	20040211		
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	CN 1129597	B	20031203	CN 1998-809385	19980724
	ES 2213286	T3	20040816	ES 1998-933922	19980724
	US 6251900	B1	20010626	US 2000-463214	20000121
PRAI	JP 1997-198804	A	19970724		
	WO 1998-JP3308	W	19980724		

OS MARPAT 130:153673

IT 220228-61-5P 220228-62-6P 220228-63-7P  
 220228-64-8P 220228-65-9P 220228-66-0P  
 220228-68-2P 220228-69-3P 220228-70-6P  
 220228-71-7P 220228-72-8P 220228-73-9P  
 220228-74-0P 220228-75-1P 220228-76-2P  
 220228-77-3P 220228-78-4P 220228-79-5P  
 220228-80-8P 220228-81-9P 220228-82-0P  
 220228-83-1P 220228-84-2P 220228-85-3P  
 220228-86-4P 220228-87-5P 220228-88-6P  
 220228-89-7P 220228-90-0P 220228-91-1P  
 220228-92-2P 220228-93-3P 220228-94-4P  
 220228-95-5P 220228-96-6P 220228-97-7P  
 220228-98-8P 220228-99-9P 220229-00-5P  
 220229-01-6P 220229-02-7P 220229-04-9P  
 220229-05-0P 220229-07-2P 220229-14-1P  
 220229-15-2P 220229-16-3P 220229-18-5P  
 220229-20-9P 220229-21-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as antitumor agents)

RN 220228-61-5 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-62-6 CAPLUS


10523,245

CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)




RN 220228-63-7 CAPLUS

CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 220228-64-8 CAPLUS

CN 1,3,5-Triazine-2-carbonitrile, 4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 220228-65-9 CAPLUS


CN 4-Piperidinol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



10523,245

RN 220228-66-0 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-[3-(trifluoromethyl)-4-morpholinyl]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-68-2 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-69-3 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245

RN 220228-70-6 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-71-7 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-[(3S,5R)-3,5-dimethyl-4-morpholinyl]-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220228-72-8 CAPLUS


CN 1H-Benzimidazole, 1-[4-(3,3-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-73-9 CAPLUS


10523,245

CN 1H-Benzimidazole, 1-[4-(3-ethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-74-0 CAPLUS


CN 1H-Benzimidazole, 1-[4-[3-(chloromethyl)-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-75-1 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5R)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-76-2 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245




RN 220228-77-3 CAPLUS

CN 1H-Benzimidazole, 1-[4-(3-methyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 220228-78-4 CAPLUS

CN 1H-Benzimidazole, 1-[4-(3-methyl-4-morpholinyl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-79-5 CAPLUS


CN Carbamic acid, [[4-[4-(1H-benzimidazol-1-yl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]-3-morpholinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10523,245


RN 220228-80-8 CAPLUS

CN 1H-Benzimidazole, 5,6-dimethyl-1-[4-(4-morpholinyl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 220228-81-9 CAPLUS

CN 3-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 220228-82-0 CAPLUS

CN 1H-Benzimidazole, 1-[4-[3-(fluoromethyl)-4-morpholinyl]-6-(1-piperazinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 220228-83-1 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245



RN 220228-84-2 CAPLUS


CN 3-Morpholinemethanol, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-85-3 CAPLUS

CN 1H-Benzimidazole, 1-[4,6-bis[(3R,5S)-3,5-dimethyl-4-morpholinyl]-1,3,5-triazin-2-yl]-2,5,6-trimethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-86-4 CAPLUS


CN 3-Piperidinol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245




RN 220228-87-5 CAPLUS

CN 4-Piperidinone, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-88-6 CAPLUS


CN 4-Piperidinol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 220228-89-7 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-methyl-1-piperazinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245




RN 220228-90-0 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-(1H-benzimidazol-1-yl)-N,N-dimethyl-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 220228-91-1 CAPLUS

CN Ethanol, 2-[[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]methylamino]- (9CI) (CA INDEX NAME)




RN 220228-92-2 CAPLUS

CN Ethanol, 2,2'-[[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 220228-93-3 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 220228-94-4 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-(1H-benzimidazol-1-yl)-N-ethyl-6-(4-morpholinyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 220228-95-5 CAPLUS

CN Carbamic acid, [4-[1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-3-piperidinyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 220228-96-6 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-6-(4-thiomorpholinyl)-1,3,5-triazin-2-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 220228-97-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-98-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5R)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245

RN 220228-99-9 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220229-00-5 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220229-01-6 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(4-thiomorpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10523,245


RN 220229-02-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(1-piperazinyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




RN 220229-04-9 CAPLUS

CN Carbamic acid, [[4-[2-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-4-pyrimidinyl]-3-morpholinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 220229-05-0 CAPLUS


CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 220229-07-2 CAPLUS

CN 1H-Benzimidazole, 1,1'-[6-(4-morpholinyl)-2,4-pyrimidinediyl]bis- (9CI)  
(CA INDEX NAME)


10523,245



RN 220229-14-1 CAPLUS  
CN 1H-Benzimidazole, 1-(5-bromo-4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI)  
(CA INDEX NAME)



RN 220229-15-2 CAPLUS  
CN 3-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 220229-16-3 CAPLUS  
CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




10523,245



● HCl

RN 220229-18-5 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(1-piperazinyl)-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 220229-20-9 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-(1H-benzimidazol-1-yl)-N-ethyl-6-(4-morpholinyl)-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 220229-21-0 CAPLUS

CN 3-Piperidinebutanamine, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-

10523,245

1,3,5-triazin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 220229-25-4P 220229-29-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as antitumor agents)


RN 220229-25-4 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220229-29-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
24.18	186.15

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 10:39:18 ON 10 DEC 2005